New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

February 6, 2024

https://www.globenewswire.com/news-release/2024/02/06/2824381/26106/en/New-Case-Series-Demonstrates-Potential-of-Aquadex-Therapy-for-End-Stage-Liver-Disease-Patients-with-Fluid-Overload.html

MINNEAPOLIS, Feb. 06, 2024 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the publication of new data demonstrating the potential value of the Aquadex SmartFlow® system’s aquapheresis therapy when treating patients with fluid overload as a result of end-stage liver disease. The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation.

Read more at globenewswire.com

Related news for (NUWE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.